Results 111 to 120 of about 90,167 (303)

BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single [PDF]

, 2010
Aims: To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Department of Hospital de Santa Maria using the BioRePortAP.
Campanilho-Marques, R., Canhao, Helena, Costa, M., Fonseca, João Eurico, Martins, F., Pereira da Silva, José A., Polido-Pereira, J., Ramos, F., Rodrigues, A., Saavedra, M. J.   +9 more
core  

Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN‐DU study

Arthritis &Rheumatology, Accepted Article.
Objective To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of juvenile idiopathic arthritis (JIA) patients. Methods The international UCAN CAN‐DU study prospectively enrolls JIA patients across Canada and the Netherlands.
Jelleke B. de Jonge, Sytze de Roock, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Deborah A. Marshall, Sebastiaan J. Vastert, Rae S.M. Yeung, Joost F. Swart, Susanne M. Benseler, The UCAN CAN‐DU and UCAN CURE consortia, Adam Huber, Alan Rosenberg, Alexander Mosoiu, Alisa Rachlis, Amy Xu, Andrea Human, Annet van Royen‐Kerkhof, Arthur Cheng, Berent Prakken, Bianca Lang, Brenleigh Jebb, Brian Feldman, Bruno Pereira, Chelsea DeCoste, Ciarán Duffy, Claire LeBlanc, Clare Hutchinson, Daniah Basodan, Danielle Brinkman, David Cabral, Dax G. Rumsey, Deborah Levy, Dilan Dissanayake, Elizabeth Legger, Elizabeth Stringer, Elizaveta Limenis, Ellen Schatorje, Elodie Boudes, Erika Van Nieuwenhove, Erkan Demirkaya, Esther Hoppenreijs, Evelyn Rozenblyum, Gaëlle Chédeville, Gillian Currie, Giske Biesbroek, Gordon Soon, Harper Cheng, Heinrike Schmeling, Herman Tam, Hon Yan Ng, Jaime Guzman, Jeanine McColl, Jennifer Ji Young Lee, Jonathan Park, Joseph Cafazzo, Kate Neufeld, Kim Morishita, Kristin Houghton, Liane Heale, Lillian Lim, Lily Lim, Lori Tucker, Lynn Spiegel, Maarten IJzerman, Marc Jansen, Mariken Gruppen, Marinka Twilt, Marleen Verkaaik, Mehul Jariwala, Mercedes Chan, Michelle Batthish, Michelle Kip, Muhammed Dhalla, Nadia Luca, Nickolas Blanchette, Nico Wulffraat, Nicole Johnson, Paivi Miettunen, Paul Dancey, Petra Hissink Muller, Philomine van Pelt, Piya Lahiry, Ravneet Sran, Rayfel Schneider, Rebeka Stevenson, Regina de Geus, Roberta Berard, Roman Jurencak, Ronald Laxer, Rosie Scuccimarri, Ross Petty, Ruud Verstegen, Sarah Campillo, Shirley Tse, Suzanne Ramsey, Sylvia Kamphuis, Tala El Tal, Tania Cellucci, Tara McGrath, Tommy Gerschman, Trang Duong, Tristan Kerr, Wineke Armbrust   +102 more
wiley   +1 more source

Mortality trends in a Cohort of Canadian Psoriatic Arthritis Patients

McGill Journal of Medicine, 2020
Methods: We reviewed retrospectively the charts of psoriatic arthritis patients who died from 1995-2010.We included 13 deceased patients with a psoriatic arthritis di-agnosis and compared them with 140 patients living with psoriatic arthritis that at ...
Boluwaji Ogunyemi
doaj  

The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study [PDF]

, 2017
Background: In this study, we sought to compare the performance of spondyloarthritis (SpA) classification criteria sets in an international SpA cohort with patients included from five continents around the world.
Bakker, Pauline, Dougados, Maxime, Etcheto, Adrien, Landewé, Robert, Moltó, Anna, Van den Bosch, Filip, van der Heijde, Désirée, van Gaalen, Floris   +7 more
core   +2 more sources

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Arthritis &Rheumatology, Accepted Article.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase III, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, The Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)   +21 more
wiley   +1 more source

AB0020B QUANTIFYING DIFFERENCES IN HERITABILITY AMONG PSORIATIC ARTHRITIS (PSA), CUTANEOUS PSORIASIS (PSC) AND PSORIASIS VULGARIS (PSV) [PDF]

, 2019
Quan Li, Vinod Chandran, Lam C. Tsoi, Rajan P. Nair, Dafna D. Gladman, James T. Elder, Proton Rahman   +6 more
openalex   +1 more source

Translational Research Studies Unraveling the Origins of Psoriatic Arthritis: Moving Beyond Skin and Joints [PDF]

, 2021
Janne W. Bolt, Chaja M. J. van Ansenwoude, Ihsan Hammoura, Marleen G. van de Sande, Lisa G. M. van Baarsen   +4 more
openalex   +1 more source

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice

British Journal of Clinical Pharmacology, EarlyView.
Aims Adherence to disease‐modifying antirheumatic drugs (DMARDs) has been associated with improved treatment outcomes, but how adherence is reported ranges between studies. We therefore aimed to determine how nonadherence to DMARDs used to treat rheumatoid arthritis (RA) has been measured and to report the nonadherence rate with each measure identified.
Lauren Fraser, Nagham Ailabouni, Lisa Kalisch Ellett, Jiun Ming Tan, Anthea Freeman, Susanna M. Proudman, Emily Reeve, Michael D. Wiese   +7 more
wiley   +1 more source

214. Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis and Current Skin Involvement: Results of Palace 3, a Phase 3, Randomized, Controlled Trial [PDF]

, 2014
Christopher J. Edwards, Francisco J. Blanco, Jeffrey Crowley, ChiaChi Hu, Randall M. Stevens, C. Birbara   +5 more
openalex   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source